סך נכסי הפעילות העסקית Singular Genomics Systems Inc (OMIC)

The price evolution of Singular Genomics Systems (OMIC), whose total assets reach 235.53, is based on the consolidation of production capacities and laboratories in California to ensure output quality. Demand for genome analysis systems is moderately volatile, as equipment procurement is often tied to the volume of government subsidies. Meanwhile, plants operate on schedule, regularly updating lithography equipment in sterile chip fabrication cleanrooms.

Assessing the financial stability of Singular Genomics Systems requires an analysis of the aggregate resources supporting the development of energy-efficient, sustainable genomic technologies. This indicator, reverse-calculated via ROA, combines equity and liabilities, allowing consolidated asset trends to determine the balance between scaling the production base and capital management efficiency to minimize investment risks.